Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-26 00:00:00 ET · period of report 2025-02-24 · accession 0000875320-25-000115 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-26 | 2025-02-24 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $483.28 | -3,310 | 64.4K | -5% | -$1.60M | |
| 2025-02-26 | 2025-02-25 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $480.95 | -354 | 64.0K | -0.5% | -$170.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-24 | F | D | 3,310 | $483.28 | 64,385 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-25 | S | D | 354 | $480.95 | 64,031 | D | — | — |